Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF.
暂无分享,去创建一个
Akshay S. Desai | S. Solomon | A. Desai | J. McMurray | M. Vaduganathan | S. Anker | M. Packer | S. Janssens | D. Miličić | B. Claggett | M. Lefkowitz | V. Shi | S. Perrone | J. L. Arango
[1] I. Piña,et al. PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. , 2020, American heart journal.
[2] P. Ponikowski,et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.
[3] Christopher L. Roy,et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2019, Journal of the American College of Cardiology.
[4] Akshay S. Desai,et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.
[5] Akshay S. Desai,et al. Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. , 2019, Circulation. Heart failure.
[6] S. Solomon,et al. Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction , 2019, JAMA network open.
[7] Akshay S. Desai,et al. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. , 2019, Circulation.
[8] I. Piña,et al. Abstract 252: PredischaRge Initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial , 2019, Circulation: Cardiovascular Quality and Outcomes.
[9] Akshay S. Desai,et al. Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. , 2019, JACC. Heart failure.
[10] G. David,et al. The effect of predictive analytics-driven interventions on healthcare utilization. , 2019, Journal of health economics.
[11] E. Braunwald,et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.
[12] M. Vaduganathan,et al. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. , 2019, JACC. Heart failure.
[13] R. Califf,et al. Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points: From the ASCEND-HF Trial , 2018, Circulation. Cardiovascular quality and outcomes.
[14] Akshay S. Desai,et al. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial , 2018, JAMA cardiology.
[15] C. Izumi,et al. Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics? , 2018, European heart journal.
[16] Roland A Matsouaka,et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. , 2017, Journal of the American College of Cardiology.
[17] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.
[18] Akshay S. Desai,et al. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. , 2016, Journal of the American College of Cardiology.
[19] M. Vaduganathan,et al. The vulnerable phase after hospitalization for heart failure , 2015, Nature Reviews Cardiology.
[20] Akshay S. Desai,et al. Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction , 2014, Circulation. Heart failure.
[21] Akshay S. Desai,et al. Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction , 2013, Circulation. Heart failure.
[22] M. Vaduganathan,et al. Thirty-day readmissions: the clock is ticking. , 2013, JAMA.
[23] Karl Swedberg,et al. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.
[24] V. Hasselblad,et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.
[25] Zhiliang Ying,et al. Semiparametric regression for the mean and rate functions of recurrent events , 2000 .